Content
All Posts > Content under Pharma/Biotech
Week In Review: Zai Lab Completes Second Listing With $761 Million HK IPO
Article By:
ChinaBio® Today
Read
Saturday, October 3, 2020 2:17 PM EDT
Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion. XtalPi closed a $318.8 million oversubscribed Series C funding co-led by SoftBank Vision Fund2, PICC Capital, and Morningside
Cannabis Central: Pure-Play Pot Stocks Crash In September; Only 2 Advance
Article By:
Lorimer Wilson
Read
Thursday, October 1, 2020 9:14 AM EDT
Only 25 of about 250 actively traded pot stocks meet the criteria for inclusion in the Pure-Play Pot Stock Portfolio of being pure-play cannabis companies whose stocks consistently trade for at least US$1/share and the portfolio crashed in September.
Market Briefing For Wednesday, Sept. 30
Article By:
Gene Inger
Read
Wednesday, September 30, 2020 2:40 AM EDT
The market pattern hasn't changed, it progresses and ideally will digest the Debate and 'try' to advance further.
TalkMarkets Tuesday Talk: Dips, Swings And The Election
Article By:
TalkMarkets DailyTalk
Read
Tuesday, September 29, 2020 7:40 AM EDT
With the markets swinging up yesterday and Friday, it seems that last week's ride lower in the markets may have been a dip rather than a downturn. Will higher levels hold sway?
In this article: IWM, NDX, SPX, AZN, BMY, BRK-A, GSK, MRK, RHHBY, GNMK, NVAX, OSUR, QDEL, HOLX, PACB, MRNA, ABBV, AXDX, EDIT, CRSP, D, UNG, XLE, UUP
Biotech Stock Playbook In A Choppy Momentum Market
Article By:
Rod Raynovich
Read
Tuesday, September 29, 2020 4:57 AM EDT
Biotech stocks peaked in mid-July but we have assumed a fourth quarter rally driven by clinical news in oncology and important scientific breakthroughs in diagnostic testing for coronavirus and COVID vaccine data.
In this article: ABT, AZN, BMY, GSK, JNJ, MRK, RHHBY, GNMK, NVAX, OSUR, QDEL, HOLX, PACB, ABBV, AXDX, EDIT, CRSP
Biotech Tools Boost 10X Genetics
Article By:
MoneyShow.com
Read
Saturday, September 26, 2020 4:23 PM EDT
Scientists don’t know why some people with a particular variation in their DNA develop cancer, while others with the same variation don’t. 10X Genomics' technology suite enables the study of cells and systems at an unprecedented level of resolution.
In this article: TXG
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Week In Review: Illumina Pays $8 Billion To Acquire GRAIL, An Early-Stage Cancer Testing Company
Article By:
ChinaBio® Today
Read
Saturday, September 26, 2020 1:33 PM EDT
Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. JD Health, a Beijing online healthcare company, plans to raise $3 billion in a Hong Kong IPO.
J&J In Final Stage COVID-19 Tests: Would You Take The Vaccine?
Article By:
Mish Shedlock
Read
Thursday, September 24, 2020 4:20 AM EDT
Johnson & Johnson (JNJ) starts a 60,000 person phase-3 trial test. Stage-3 is the final phase.
Open Source Licensing Could Keep Big Pharma From Making Huge Profits Off Taxpayer-Funded Research
Article By:
The Conversation
Read
Wednesday, September 23, 2020 5:25 AM EDT
An international, multi-billion-dollar race is underway to develop a COVID-19 vaccine, and progress is moving at record speed, but with nationalistic, competitive undertones.